Clinical Trial Detail

NCT ID NCT04231864
Title Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alain Algazi
Indications

nasopharynx carcinoma

Therapies

Durvalumab + Epacadostat

Age Groups: senior adult

No variant requirements are available.